Latest news with #MoonpigGroup
Yahoo
24-07-2025
- Business
- Yahoo
3 UK Stocks That Investors May Be Undervaluing By Up To 35.3%
The United Kingdom's FTSE 100 and FTSE 250 indices have experienced declines, influenced by weak trade data from China and its sluggish economic recovery efforts. In this challenging environment, identifying undervalued stocks can be crucial for investors seeking opportunities; these are stocks that may not yet reflect their true potential value amidst broader market pressures. Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom Name Current Price Fair Value (Est) Discount (Est) Vistry Group (LSE:VTY) £6.196 £11.80 47.5% Van Elle Holdings (AIM:VANL) £0.38 £0.74 49% Topps Tiles (LSE:TPT) £0.378 £0.7 45.7% TBC Bank Group (LSE:TBCG) £47.95 £94.76 49.4% Moonpig Group (LSE:MOON) £2.115 £4.02 47.4% Marlowe (AIM:MRL) £4.43 £8.39 47.2% LSL Property Services (LSE:LSL) £3.02 £5.85 48.4% Gooch & Housego (AIM:GHH) £6.06 £11.18 45.8% Franchise Brands (AIM:FRAN) £1.40 £2.69 47.9% Begbies Traynor Group (AIM:BEG) £1.21 £2.26 46.4% Click here to see the full list of 54 stocks from our Undervalued UK Stocks Based On Cash Flows screener. Let's uncover some gems from our specialized screener. Tristel Overview: Tristel plc develops, manufactures, and sells infection prevention products across the United Kingdom, Australia, Germany, Western Europe, and internationally with a market cap of £186.08 million. Operations: The company's revenue is primarily derived from its Hospital Medical Device Decontamination segment at £37.68 million, followed by Hospital Environmental Surface Disinfection at £3.51 million. Estimated Discount To Fair Value: 10% Tristel is trading at £3.9, below its estimated fair value of £4.34, highlighting potential undervaluation based on cash flows. The company's earnings have consistently grown by 10% annually over the past five years and are projected to grow faster than the UK market at 19% per year. Recent FDA clearance for Tristel OPH in the U.S. could enhance revenue growth prospects, though dividend coverage remains a concern with a yield of 3.47%. According our earnings growth report, there's an indication that Tristel might be ready to expand. Delve into the full analysis health report here for a deeper understanding of Tristel. ConvaTec Group Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies globally with a market cap of £4.96 billion. Operations: The company's revenue segment comprises the development, manufacture, and sale of medical products and technologies, generating $2.29 billion. Estimated Discount To Fair Value: 35.3% ConvaTec Group is trading at £2.43, significantly below its estimated fair value of £3.75, indicating undervaluation based on cash flows. Despite a high debt level, the company has shown strong earnings growth of 46.2% over the past year and is expected to outpace UK market growth with projected earnings increases of 16.82% annually. Revenue growth forecasts also exceed market expectations at 5.6% per year, supporting a positive outlook for future cash flows. Our earnings growth report unveils the potential for significant increases in ConvaTec Group's future results. Click here and access our complete balance sheet health report to understand the dynamics of ConvaTec Group. Foresight Group Holdings Overview: Foresight Group Holdings Limited is an infrastructure and private equity manager operating in the United Kingdom, Italy, Luxembourg, Ireland, Spain, and Australia with a market cap of £511.62 million. Operations: The company's revenue is derived from three segments: Infrastructure (£95.89 million), Private Equity (£50.52 million), and Foresight Capital Management (£7.58 million). Estimated Discount To Fair Value: 13.9% Foresight Group Holdings is trading at £4.56, below its estimated fair value of £5.3, reflecting potential undervaluation based on cash flows. The company reported a net income increase to £33.25 million for the year ended March 31, 2025, and earnings per share growth, highlighting robust financial health. With forecasted earnings growth of 18.6% annually and revenue growth outpacing the UK market at 9.5% per year, Foresight remains focused on strategic acquisitions using its strong cash generation capabilities. Our growth report here indicates Foresight Group Holdings may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in Foresight Group Holdings' balance sheet health report. Turning Ideas Into Actions Gain an insight into the universe of 54 Undervalued UK Stocks Based On Cash Flows by clicking here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Interested In Other Possibilities? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:TSTL LSE:CTEC and LSE:FSG. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
21-02-2025
- Business
- Yahoo
Why Moonpig Group PLC (LON:MOON) Could Be Worth Watching
Moonpig Group PLC (LON:MOON), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in the past couple of months on the LSE. While good news for shareholders, the company has traded much higher in the past year. As a stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. But what if there is still an opportunity to buy? Today we will analyse the most recent data on Moonpig Group's outlook and valuation to see if the opportunity still exists. View our latest analysis for Moonpig Group Great news for investors – Moonpig Group is still trading at a fairly cheap price. According to our valuation, the intrinsic value for the stock is £3.48, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that Moonpig Group's share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility. Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Moonpig Group's revenue growth are expected to be in the teens in the upcoming years, indicating a solid future ahead. Unless expenses grow at the same level, or higher, this top-line growth should lead to robust cash flows, feeding into a higher share value. Are you a shareholder? Since MOON is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation. Are you a potential investor? If you've been keeping an eye on MOON for a while, now might be the time to enter the stock. Its buoyant future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy MOON. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision. If you want to dive deeper into Moonpig Group, you'd also look into what risks it is currently facing. Every company has risks, and we've spotted 2 warning signs for Moonpig Group (of which 1 shouldn't be ignored!) you should know about. If you are no longer interested in Moonpig Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
